JP2023520333A5 - - Google Patents
Info
- Publication number
- JP2023520333A5 JP2023520333A5 JP2022557856A JP2022557856A JP2023520333A5 JP 2023520333 A5 JP2023520333 A5 JP 2023520333A5 JP 2022557856 A JP2022557856 A JP 2022557856A JP 2022557856 A JP2022557856 A JP 2022557856A JP 2023520333 A5 JP2023520333 A5 JP 2023520333A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- alkyl
- inhibitor
- pharmaceutical product
- product according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062993889P | 2020-03-24 | 2020-03-24 | |
| US62/993,889 | 2020-03-24 | ||
| PCT/US2021/023752 WO2021195128A1 (en) | 2020-03-24 | 2021-03-23 | Eif4a inhibitor combinations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023520333A JP2023520333A (ja) | 2023-05-17 |
| JP2023520333A5 true JP2023520333A5 (cg-RX-API-DMAC7.html) | 2024-04-03 |
Family
ID=77855108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022557856A Pending JP2023520333A (ja) | 2020-03-24 | 2021-03-23 | Eif4a阻害剤組み合わせ |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210299111A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4125884A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023520333A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230005175A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115996716A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021244462A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3176264A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021195128A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023030687A1 (en) | 2021-09-01 | 2023-03-09 | KHR Biotec GmbH | Cyclopenta[4,5]furo[3,2-c]pyridine derivatives as ras inhibitors for use in the treatment of hyperproliferative diseases or genetic disorders |
| CN117982498A (zh) * | 2022-11-01 | 2024-05-07 | 苏州开拓药业股份有限公司 | 一种含蛋白降解剂或抑制剂的组合物及其用途 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| WO2024254195A1 (en) * | 2023-06-06 | 2024-12-12 | Baylor University | Methods for treating pancreatic cancer with a combination of des-methyl pateamine a and a class 1 hdac inhibitor |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| CN119351519B (zh) * | 2024-10-21 | 2025-08-01 | 吉林大学 | 一种靶向隐孢子虫解旋酶的抗隐孢子虫小分子先导化合物 |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102011111400A1 (de) * | 2011-08-23 | 2013-02-28 | Merck Patent Gmbh | Bicyclische heteroaromatische Verbindungen |
| EP3191098A4 (en) * | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| KR102934754B1 (ko) * | 2015-11-25 | 2026-03-04 | 이펙터 테라퓨틱스, 인크. | Eif4a-억제 화합물 및 이에 관련된 방법 |
| CA3063563A1 (en) * | 2017-05-24 | 2018-11-29 | Effector Therapeutics, Inc. | Compositions and methods for an improved antitumor immune response |
-
2021
- 2021-03-23 CN CN202180037497.2A patent/CN115996716A/zh active Pending
- 2021-03-23 WO PCT/US2021/023752 patent/WO2021195128A1/en not_active Ceased
- 2021-03-23 EP EP21776812.6A patent/EP4125884A4/en not_active Withdrawn
- 2021-03-23 CA CA3176264A patent/CA3176264A1/en active Pending
- 2021-03-23 KR KR1020227036983A patent/KR20230005175A/ko active Pending
- 2021-03-23 JP JP2022557856A patent/JP2023520333A/ja active Pending
- 2021-03-23 US US17/210,062 patent/US20210299111A1/en not_active Abandoned
- 2021-03-23 AU AU2021244462A patent/AU2021244462A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2911040T3 (es) | Nuevos derivados de heteroaril amida como inhibidores selectivos de histona deacetilasa 1 y 2 (HDAC1/2) | |
| US20090041716A1 (en) | Crystalline form of methyl ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1((2s)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1h-imidazol-5-yl)-4-biphenylyl)-1h-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt | |
| BR112020001695A2 (pt) | compostos macrocíclicos e usos dos mesmos | |
| JP2019517487A5 (cg-RX-API-DMAC7.html) | ||
| JP2011509309A5 (cg-RX-API-DMAC7.html) | ||
| WO2012143248A1 (en) | Substituted pyrimidinyl-pyrroles active as kinase inhibitors | |
| JP2023536164A5 (cg-RX-API-DMAC7.html) | ||
| JP5695200B2 (ja) | 複素環アミノベルバミン誘導体、その調製方法及び使用 | |
| JP2020505395A5 (cg-RX-API-DMAC7.html) | ||
| US10947225B2 (en) | Phosphotidylinositol 3-kinase inhibitors | |
| JP2007515419A5 (cg-RX-API-DMAC7.html) | ||
| JP2016525104A5 (cg-RX-API-DMAC7.html) | ||
| US9714235B2 (en) | Quinazoline derivatives, compositions thereof, and use as pharmaceuticals | |
| CN111511745A (zh) | 吡唑并[1,5-a][1,3,5]三嗪-2-胺类衍生物、其制备方法及其在医药上的应用 | |
| WO2022083657A1 (zh) | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 | |
| US20160229857A1 (en) | Substituted pyrrolo[2,3-d]dipyrimidines for selectively targeting tumor cells with fr-alpha and fr-beta type receptors | |
| JP2017137323A (ja) | 新規抗がん剤 | |
| CN110520118A (zh) | 谷氨酰胺类似物的前药 | |
| CA3119036A1 (en) | Anti-cancer activity of adamantane derivatives | |
| WO2018117196A1 (ja) | がん幹細胞を標的とする医薬 | |
| CA3195465A1 (en) | Succinate and crystal form thereof as therapeutics | |
| CN101265275B (zh) | 4-{6-[5-(2-氯-6-甲基苯胺甲酰基)-噻唑-2-氨基]-2-甲基嘧啶-4}-哌嗪-1-磷酸二乙酯 | |
| JP2022502378A5 (cg-RX-API-DMAC7.html) | ||
| JP2015531355A (ja) | 腫瘍治療のための薬剤組成物及びその適用 | |
| US10093609B2 (en) | TAK1 kinase inhibitors, compositions, and uses related thereto |